Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Zolgensma shows that a gene therapy can be a commercial hit - but there's still plenty to be wary of in this cutting-edge field.
You may also be interested in...
Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.